These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20946973)

  • 1. Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine?
    Salvadore G; Zarate CA
    Biol Psychiatry; 2010 Nov; 68(9):780-2. PubMed ID: 20946973
    [No Abstract]   [Full Text] [Related]  

  • 2. GABA and glutamate systems as therapeutic targets in depression and mood disorders.
    Kendell SF; Krystal JH; Sanacora G
    Expert Opin Ther Targets; 2005 Feb; 9(1):153-68. PubMed ID: 15757488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Translational Potential of Non-coding RNAs and Multimodal MRI Data Sets as Diagnostic and Differential Diagnostic Biomarkers for Mood Disorders.
    Todeva-Radneva A; Aryutova K; Kandilarova S; Paunova R; Stoyanov D
    Curr Top Med Chem; 2021; 21(11):949-963. PubMed ID: 34355686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
    Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
    Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.
    Yüksel C; Öngür D
    Biol Psychiatry; 2010 Nov; 68(9):785-94. PubMed ID: 20728076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From the Editor-in-Chief's Desk: Precision Classification and Treatment of Early Life Mood Disorders for Improved Outcomes.
    Croarkin PE
    J Child Adolesc Psychopharmacol; 2024 May; 34(4):165-166. PubMed ID: 38709161
    [No Abstract]   [Full Text] [Related]  

  • 7. Personalized Medicine and Mood Disorders.
    Alhajji L; Nemeroff CB
    Psychiatr Clin North Am; 2015 Sep; 38(3):395-403. PubMed ID: 26300030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized medicine: Prediction of disease vulnerability in mood disorders.
    Prendes-Alvarez S; Nemeroff CB
    Neurosci Lett; 2018 Mar; 669():10-13. PubMed ID: 27746310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets.
    Małgorzata P; Paweł K; Iwona ML; Brzostek T; Andrzej P
    Expert Opin Ther Targets; 2020 Dec; 24(12):1187-1209. PubMed ID: 33138678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glutamatergic conception of mood disorders].
    Permoda-Osip A; Rybakowski J
    Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Spectroscopy for Psychiatry: Progress in the Last Decade.
    Port JD
    Neuroimaging Clin N Am; 2020 Feb; 30(1):25-33. PubMed ID: 31759569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and challenges in development of precision psychiatry through clinical metabolomics on mood and psychotic disorders.
    Pedrini M; Cao B; Nani JVS; Cerqueira RO; Mansur RB; Tasic L; Hayashi MAF; McIntyre RS; Brietzke E
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jul; 93():182-188. PubMed ID: 30904564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.
    Duarte JMN; Xin L
    Neurochem Res; 2019 Jan; 44(1):102-116. PubMed ID: 29616444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human biomarkers of rapid antidepressant effects.
    Zarate CA; Mathews DC; Furey ML
    Biol Psychiatry; 2013 Jun; 73(12):1142-55. PubMed ID: 23374639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics.
    Carreon RL; Rivas-Grajales AM; Murphy N; Mathew SJ; Jha MK
    Adv Neurobiol; 2023; 30():287-297. PubMed ID: 36928855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed circadian phase is linked to glutamatergic functions in young people with affective disorders: a proton magnetic resonance spectroscopy study.
    Naismith SL; Lagopoulos J; Hermens DF; White D; Duffy SL; Robillard R; Scott EM; Hickie IB
    BMC Psychiatry; 2014 Dec; 14():345. PubMed ID: 25496061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opinion Paper: Modular Drug Delivery Systems for Personalized Oral Dosage Forms.
    Colombo P
    Recent Pat Drug Deliv Formul; 2016; 10(1):3. PubMed ID: 26063397
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolomics: moving to the clinic.
    Nordström A; Lewensohn R
    J Neuroimmune Pharmacol; 2010 Mar; 5(1):4-17. PubMed ID: 19399626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
    Stone JM
    Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse childhood experiences associate to reduced glutamate levels in the hippocampus of patients affected by mood disorders.
    Poletti S; Locatelli C; Falini A; Colombo C; Benedetti F
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():117-22. PubMed ID: 27449360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.